KR20240163751A - Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 - Google Patents
Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR20240163751A KR20240163751A KR1020247036173A KR20247036173A KR20240163751A KR 20240163751 A KR20240163751 A KR 20240163751A KR 1020247036173 A KR1020247036173 A KR 1020247036173A KR 20247036173 A KR20247036173 A KR 20247036173A KR 20240163751 A KR20240163751 A KR 20240163751A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- set forth
- sequence set
- bispecific antibody
- nrp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325312P | 2022-03-30 | 2022-03-30 | |
| US202263325317P | 2022-03-30 | 2022-03-30 | |
| US63/325,312 | 2022-03-30 | ||
| US63/325,317 | 2022-03-30 | ||
| PCT/US2023/016963 WO2023192514A1 (en) | 2022-03-30 | 2023-03-30 | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240163751A true KR20240163751A (ko) | 2024-11-19 |
Family
ID=86184900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247036173A Pending KR20240163751A (ko) | 2022-03-30 | 2023-03-30 | Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12692315B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499696A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7871988B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240163751A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403831A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023245728A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255754A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002899A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024014799A2 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240462A (cg-RX-API-DMAC7.html) |
| IL (1) | IL315960A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011978A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023192514A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315960A (en) | 2022-03-30 | 2024-11-01 | Pinetree Therapeutics Inc | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| AU2023317484A1 (en) * | 2022-07-30 | 2025-03-13 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradaton and methods of use thereof |
| IL320410A (en) * | 2022-11-07 | 2025-06-01 | Pinetree Therapeutics Inc | Combination therapy involving bispecific antibodies containing an NRP1 binding domain |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| US6302874B1 (en) | 1998-07-13 | 2001-10-16 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗her2抗体改変体 |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
| CA2628253A1 (en) | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| US20100143340A1 (en) | 2006-12-13 | 2010-06-10 | Schering Corporation | Methods and compositions for treating cancer |
| PL2155788T3 (pl) * | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| WO2010099186A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Her2 antibody compositions |
| EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| WO2011057064A1 (en) | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| WO2011143408A1 (en) | 2010-05-13 | 2011-11-17 | Genentech, Inc. | Use of neuropilin-1 antagonists for the treatment of cancer |
| JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
| AU2012255920A1 (en) | 2011-05-18 | 2013-11-07 | Merck Sharp & Dohme Corp. | Therapeutic anti-IGF1R combinations |
| CN102492039B (zh) | 2011-11-21 | 2015-03-11 | 无锡天演生物技术有限公司 | 全人源抗人her2单抗 |
| EP2863947B1 (en) | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| WO2014189303A1 (ko) | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
| JP6541237B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子1受容体特異的抗体及びそれらの使用 |
| EP3114142B1 (en) | 2014-03-06 | 2019-06-05 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| US9975960B2 (en) | 2014-05-09 | 2018-05-22 | Samsung Electronics Co., Ltd. | Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same |
| KR101551306B1 (ko) | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
| ES3043088T3 (en) | 2015-06-17 | 2025-11-24 | Hoffmann La Roche | Anti-her2 antibodies and methods of use |
| WO2017171373A2 (ko) * | 2016-03-29 | 2017-10-05 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| KR102048474B1 (ko) | 2016-03-29 | 2019-11-26 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| KR101985299B1 (ko) | 2016-06-03 | 2019-09-03 | 삼성전자주식회사 | 항-c-Met/항-Nrp1 이중 특이 항체 |
| US10167342B2 (en) | 2016-08-29 | 2019-01-01 | Fazel Shokri | Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment |
| LT3512882T (lt) | 2016-09-14 | 2021-06-25 | Merck Patent Gmbh | Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui |
| JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| EP3615571A1 (en) * | 2017-04-24 | 2020-03-04 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
| EP3680250A4 (en) | 2017-09-08 | 2021-07-14 | Ajou University Industry-Academic Cooperation Foundation | COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1) |
| KR102054389B1 (ko) | 2017-10-26 | 2019-12-11 | 아주대학교산학협력단 | 뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도 |
| KR102956998B1 (ko) | 2018-07-31 | 2026-04-27 | 도꾜 다이가꾸 | 새로운 결합 특이성을 항체에 부여하는 초범용법 |
| EP3867273A1 (en) | 2018-10-19 | 2021-08-25 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers |
| JP2022510218A (ja) | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| MX2021008121A (es) | 2019-01-03 | 2021-12-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer. |
| WO2022026943A2 (en) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections |
| IL315960A (en) | 2022-03-30 | 2024-11-01 | Pinetree Therapeutics Inc | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| IL320410A (en) | 2022-11-07 | 2025-06-01 | Pinetree Therapeutics Inc | Combination therapy involving bispecific antibodies containing an NRP1 binding domain |
| EP4754135A1 (en) | 2023-07-28 | 2026-06-10 | Pinetree Therapeutics, Inc. | Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof |
-
2023
- 2023-03-30 IL IL315960A patent/IL315960A/en unknown
- 2023-03-30 CN CN202380044206.1A patent/CN119403831A/zh active Pending
- 2023-03-30 US US18/128,928 patent/US12692315B2/en active Active
- 2023-03-30 CR CR20240462A patent/CR20240462A/es unknown
- 2023-03-30 CA CA3255754A patent/CA3255754A1/en active Pending
- 2023-03-30 EP EP23719560.7A patent/EP4499696A1/en active Pending
- 2023-03-30 KR KR1020247036173A patent/KR20240163751A/ko active Pending
- 2023-03-30 JP JP2024557935A patent/JP7871988B2/ja active Active
- 2023-03-30 AU AU2023245728A patent/AU2023245728A1/en active Pending
- 2023-03-30 WO PCT/US2023/016963 patent/WO2023192514A1/en not_active Ceased
-
2024
- 2024-09-27 CL CL2024002899A patent/CL2024002899A1/es unknown
- 2024-09-27 MX MX2024011978A patent/MX2024011978A/es unknown
- 2024-10-29 CO CONC2024/0014799A patent/CO2024014799A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240462A (es) | 2024-12-11 |
| AU2023245728A1 (en) | 2024-09-26 |
| JP2025511135A (ja) | 2025-04-15 |
| CA3255754A1 (en) | 2023-10-05 |
| US12692315B2 (en) | 2026-07-28 |
| CL2024002899A1 (es) | 2025-02-07 |
| EP4499696A1 (en) | 2025-02-05 |
| CO2024014799A2 (es) | 2024-11-18 |
| CN119403831A (zh) | 2025-02-07 |
| IL315960A (en) | 2024-11-01 |
| MX2024011978A (es) | 2025-02-10 |
| WO2023192514A1 (en) | 2023-10-05 |
| US20240101682A1 (en) | 2024-03-28 |
| JP7871988B2 (ja) | 2026-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180009892A1 (en) | Anti-ror1 antibodies | |
| US20240101682A1 (en) | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof | |
| AU2015339306A1 (en) | Combination therapy for cancer | |
| US20190010232A1 (en) | Checkpoint Inhibitor Bispecific Antibodies | |
| JP7719799B2 (ja) | 抗ガレクチン-9抗体およびその使用 | |
| AU2022206035B2 (en) | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof | |
| KR20240144422A (ko) | 암 치료의 단독치료법 및 병용치료법에서 il-18bp 길항제 항체 및 이의 용도 | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてegf/egfr経路を抑制するための方法および組成物 | |
| US20240398943A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| CN110636861A (zh) | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 | |
| EP4731256A1 (en) | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer | |
| JP2024509501A (ja) | 新規活性を持つhhla2結合剤 | |
| KR20260051054A (ko) | 표적화 라이소좀 분해를 위한 비-수용체 티로신 키나제 조성물 및 이의 이용 방법 | |
| KR20250044738A (ko) | 표적화 라이소좀 분해를 위한 조성물 및 이의 사용 방법 | |
| WO2023164872A1 (en) | Anti-cd39 antibodies and use thereof | |
| EA052797B1 (ru) | Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения | |
| HK40124330B (en) | Anti-cd39 antibodies and use thereof | |
| HK40124330A (en) | Anti-cd39 antibodies and use thereof | |
| HK40113788A (en) | Anti-cd39 antibodies and use thereof | |
| TW202434631A (zh) | 抗il-2抗體之使用方法 | |
| HK40019947A (en) | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |